Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553459 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2HSD11B1GNAI3GNAO1GNAI1 | |
| SCHEMBL1936310 | 0.82 | HSD11B1 (0.37) | HSD11B1GNAI3GNAO1GNAI1 | |
| SCHEMBL3316196 | 0.82 | GNAI3 (0.53) | GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL2748651 | 0.81 | KDM4E (0.53) | HSD11B1KDM4E | |
| SCHEMBL8309136 | 0.80 | HSD11B1 (0.36) | HSD11B1GNAI3GNAO1GNAI1 | |
| SCHEMBL1479844 | 0.79 | ACHE (0.52) | SMN1; SMN2HSD11B1KDM4E | |
| SCHEMBL4469088 | 0.79 | HSD11B1 (0.45) | SMN1; SMN2HSD11B1KDM4E | |
| SCHEMBL4461541 | 0.79 | ACHE (0.46) | SMN1; SMN2HSD11B1KDM4E | |
| SCHEMBL25721631 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2HSD11B1GNAI3GNAO1GNAI1 | |
| Benzene SCHEMBL27427468 | 0.79 | BRD4 (0.49) | SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | SMN1; SMN2 1897/4885HSD11B1 699/4885GNAI3 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.